Professional Documents
Culture Documents
The aim of this study was to develop a new extended release capsules of indomethacin. The
formulation has been prepared to enhance its dissolution which could provide better oral absorption of
indomethacin (IND). Therefore, the effects of the component nature, their proportion in the release rate
and the dissolution mechanism were investigated. Extended release capsules of IND were prepared by
physical mixing using plasdone (PVP K-90) and compritol-HD5 ATO (Comp) at various drug-polymer
ratios. Flow properties of the physical mixtures were evaluated by calculation of the Carrs index, angle
of repose and Hausner ratio. According to the United States Pharmacopeial (USP) drug release criteria
of IND extend release capsules, the release results of formulations F2 and F3 were found to be similar
to the USP (P < 0.05). Certain mathematical models were used for evaluation of release profiles and the
results supported by multiple regression analysis. It was observed that the best-fit model to determine
the mechanism of the formulation which has shown the highest release was Higuchi square-root of time
2
model (r = 0.969). According to the dissolution results, dissolution efficiency, relative dissolution rate
and mean dissolution time were also evaluated. The results of the study indicated that new extended
release hard gelatin capsules can be a promising alternative for the other oral formulations of IND.
Key words: Indomethacin, drug release, kinetic evaluation, hard gelatine capsule, stability, multiple regression
analysis.
INTRODUCTION
Generally known as an analgesic and antipyretic drug,
Indomethacin (IND) refers to the compound 1-(4-chlorobenzoyl)-5-methoxy-2-methyl-IH-indole-3-acetic acid. It
should be used attentively unlike any simple analgesic
due to its potential adverse effects (Goodman and
Gilman, 1980). Its areas of use could be listed as follows:
Treating gout, rheumatoid arthritis, relieving pain,
inhibiting cyclo-oxygenase with a diminishing effect on
prostaglandia synthesis and also on body temperature of
febric patients (Taha, 2009; Taha et al., 2009). Gastric
output of prostaglandins and intestinal maintenance of
mucoid secretion on gastrointestinal canal facing is
*Corresponding author. E-mail: aysuyurdasiper@hotmail.com
2202
(1)
Angle of repose
The angle of repose can be defined as the constant three
dimensional angle measured relatively to the horizontal base,
assumed by a cone-like pile of material formed when the powder is
passed through a funnel-like container (Khan et al., 2012; Rios,
2006; Abdullah and Geldart, 1999; Carr, 1965). Angle of repose of
the powder material was calculated by using the formula Equation
(2):
= tan
Chemicals
Indomethacin was a gift from Deva Holding Inc. (Turkey). Plasdone
(PVP K-90) was supplied by ISP, Tech. Inc. (USA), compritol-HD5
ATO was obtained from Gattefosse (France). Aerosil and avicel pH101 were given kindly from Santafarma Pharmaceuticals (Turkey).
All other chemicals and solvents were of analytical grade.
(2)
r
(2)
Aksu et al.
sample times, t^j is the time at midpoint between tj and tj-1 (easily
calculated with the expression (tj + tj-1)/2) and Mi is the additional
amount of drug dissolved between ti and ti-1. Relative dissolution
rate (RDR) is the ratio between amount of drug dissolved from
optimized formulation and that dissolved from the conventional
formulation (Gurrapu et al., 2012).
Ingredients (mg)
IND
PVP
Comp
F1
75
-
F2
75
5
F3
75
10
F4
75
5
25
F5
75
37.5
10
Kinetic evaluation
volume,V0 and the final tap volume, Vf of the powder tapping the
material until no further volume changes occur. The Hausner ratio
was calculated accoding to Equation (3) (Khan et al., 2012).
v0
Hausner ratio =
2203
3
vf
(3)
(6)
(4)
Where y is the drug percent dissolved at time t.
(5)
Where j is the sample number, n is the number of dissolution
Statistical analysis
Statistical analyses were conducted by one-way analysis of
variance (ANOVA) using target significance levels of 0.05 (P <
0.05). Multiple regression analysis was undertaken using a
computer program SPSS 10.0.
2204
Parameter
Angle of repose
Carrs index
Hausner ratio
Particle size
F1
F2
75.376.74 62.972.79
89.760.44 89.760.62
9.780.42
9.770.61
3.610.01
5.710.13
F3
49.342.71
91.600.38
11.920.55
7.340.50
F4
35.823.19
86.480.45
7.400.24
9.000.51
F5
66.707.45
84.711.75
6.590.76
5.620.41
Table 3. The percentages of indomethacin dissolved in a phosphate buffer of pH 6.2 and USP XXIII criteria of
indomethacin extend release capsules according to time.
Time (h)
1
2
4
12
F1
27.480.01
36.670.04
49.200.07
74.510.03
F2
23.710.08
45.740.05
63.960.06
99.220.04
Formulations
F3
19.680.07
37.960.06
53.090.02
82.350.05
F4
17.870.09
55.190.10
80.360.04
90.410.03
F5
49.960.05
58.900.08
66.790.03
82.200.07
Aksu et al.
2205
Figure 1. DSC thermograms of IND (F1), PVP, avicel, Comp, aerosil and F2 to F5.
2206
Formulations
F1
F2
F3
F4
F5
Zero order
Slope
r
5.183 0.886
7.788 0.867
6.464 0.867
6.791 0.693
6.258 0.724
First order
Slope
r
-0.104 0.973
-0.351 0.951
-0.146 0.976
-0.209 0.866
-0.153 0.891
Higuchi
Slope
r
22.169 0.976
33.545 0.969
27.842 0.969
30.624 0.849
24.261 0.858
Peppas
n
r
0.658 0.980
1.427 0.966
1.208 0.956
1.137 0.974
0.916 0.932
Figure 2. Comparison of release profiles using PVP and Comp by physical mixtures with pure drug (F1) (n=12).
Error bars smaller than the symbols are not shown.
Figure 3. Response surface plot of the effect of PVP concentration and time on drug release percentage (a).and PVP
concentration and Comp concentration on drug release percentage (b). and Comp concentration and time on drug release
percentage (c).
Aksu et al.
of
extended release
capsules
F5
29.10
25.74
1.82
MDT
DE (%)
RDR
F1
31.45
13.08
1.00
Formulations
F2
F3
F4
35.20
35.20
31.23
9.80
8.14
8.57
0.86
0.72
0.65
MDT
DE (%)
RDR
46.12
22.58
1.00
61.57
22.29
1.25
61.59
18.48
1.04
70.98
22.55
1.50
38.34
40.08
1.61
MDT
DE (%)
RDR
79.39
32.92
1.00
92.46
39.32
1.30
92.46
32.64
1.08
101.71
46.31
1.63
52.12
52.28
1.36
MDT
115.21
DE (%) 39.85
RDR
1.00
136.26
50.34
1.38
136.26
41.78
1.15
112.81
58.27
1.45
72.91
58.34
1.25
MDT
140.14
DE (%) 45.25
RDR
1.00
164.69
59.05
1.41
163.76
49.06
1.17
126.44
65.57
1.39
102.55
62.83
1.25
Time (h)
2207
of
Conclusion
Taken together, in this study, the effect of component
nature and the proportion at the release rate and the
mechanism were investigated by virtue of IND extended
release capsules. It was found that release results of
formulations F2 and F3 were detected to be proper to the
USP Drug Release Criteria. By this means, safety of the
drug was improved by the usage of this new capsules. It
would be an ideal formulation for 12 h release profile,
they were considered to be suitable for prescribing the
formulations for twice a day administration. It also
indicates that these capsule formulations can be an
effective dosage form for modified release formulations.
2208
F2
Initial
25C2
40C2
1
23.710.08
22.832.73
26.503.10
Time (h)
2
4
45.740.05 63.960.06
40.503.59 53.335.28
52.502.75 63.334.27
12
99.220.04
72.675.41
81.831.46
F3
Initial
25C2
40C2
19.680.07
20.331.97
31.173.13
37.960.06
41.672.87
51.002.52
82.350.05
83.832.27
78.832.11
Formulations
In conclusion, these findings suggest that the formulations F2 and F3 could be promising candidates for oral
sustained drug delivery systems, especially for poorly
soluble drugs such as IND.
ACKNOWLEDGEMENTS
We are grateful for the financial support from University
of Ege, Faculty of Pharmacy, Department of
Pharmaceutical Technology.
REFERENCES
Abdullah EC, Geldart D (1999). The use of bulk density measurements
as flowability indicators. Powder Technol. 102:151-165.
Alsaidan SA, Alsughayer AA, Eshra GA (1998). Improved dissolution
rate of Indomethacin by adsorbents. Drug Dev. Ind. Pharm. 24:389394.
Apu AS, Pathan AH, Shrestha D, Kibria G, Jalil R (2009). Investigation
of in vitro release kinetics of carbamazepine from eudragit RS PO and
RL PO matrix tablets. Trop. J. Pharm. Res. 8(2):145-152.
Carr R (1965). Evaluating flow properties of solids. Chem. Eng. 72:163168.
Dehghan MH, Jafar M (2006). Improving dissolution of meloxicam using
solid dispersions. Iran J. Pharm. Res. 4:231-238.
Edgar KJ, Buchanan CM, Debenham JS, Rundquist PA, Seiler BD,
Shelton MC, Tindall D (2001). Advances in cellulose ester
performance and application. Prog. Polym. Sci. 26(2):1605-1688.
Ege MA, Karasulu HY, Karasulu E, Ertan G (2001). A computer
program designed for in vitro dissolution kinetics, in vitro-in vivo
kinetic correlations and routine application, 4th Central European
Symposium on Pharmaceutical Technology, Vienna, Scientia
Pharmaceutica Supplement 1 Band. 69:127-S128.
Eis MJ, Watkins BM, Philip A, Welling RE (1998). Nonsteroidal-induced
benign strictures of the colon: a case-report and review of the
literature. Am. J. Gastroenterol. 93:120-121.
Elchidana PA, Deshpande SG (1999). Microporous membrane drug
delivery system for indomethacin. J. Control Release. 59(3):279-85.
Ertan G, Karasulu HY, Karasulu E, Ege MA, Kse T, Gneri T (2000). A
new in vitro/in vivo kinetic correlation method for nitrofurantoin matrix
tablet formulations. Drug Dev. Ind. pharm. 26(7):737- 743.
Friend DR (2005). New oral delivery systems for treatment of
inflammatory bowel disease. Adv. Drug Deliv. Rev. 57:247-265.
Goodman LS, Gilman A (1980). Autacoids: Drug Therapy of
Inflammation. The Pharmacological Basis of Therapeutics. In:
Goodman, LS, Gilman, A (Ed), 6th edition, Macmillan, New York, pp.
633-635.
Gurrapu A, Jukanti R, Bobbala SR, Kanuganti S, Jeevana JB (2012).
Improved oral delivery of valsartan from maltodextrin based
53.090.02
62.502.81
63.502.14
Aksu et al.
2209
Wu K, Li J, Wang W, Winstead DA (2009). Formation and characterization of solid dispersions of piroxicam and polyvinylpyrrolidone using
spray drying and precipitation with compressed antisolvent. J. Pharm.
Sci. 98(7):2422-2431.